FDA Recommends Decreased Dosage Of Lunesta
The U.S. Food and Drug Administration (FDA) has released a Safety Announcement which states: “The U.S. Food and Drug Administration (FDA) is warning that the insomnia drug Lunesta (eszopiclone) can cause next-day impairment of driving and other activities that require alertness. As a result, we have decreased the recommended starting dose of Lunesta to 1mg at bedtime. Healthcare professionals should follow the new dosing recommendations when starting patients on Lunesta. Patients should continue taking their prescribed dose of Lunesta and contact their healthcare professionals to ask about the most appropriate dose for them.”
Over the next thirty days, Carlisle Medical will be contacting physicians to inform them of this recommendation as a feature of our pharmacy management service.